Healthcare ETFs Overlook Cannabis Despite Medical Market Growth
Traditional healthcare ETFs like BBH and XPH remain absent from cannabis exposure as medical marijuana revenues surge past $7 billion annually.
Healthcare-focused exchange-traded funds continue excluding cannabis companies from their portfolios despite the medical marijuana sector generating over $7 billion in annual revenue across 38 states. Major healthcare ETFs including the VanEck Biotech ETF (BBH) and the SPDR S&P Pharmaceuticals ETF (XLV) maintain zero exposure to cannabis operators, even as medical cannabis prescriptions reach record levels.
The disconnect highlights institutional investment barriers that persist in cannabis markets. While pharmaceutical giants develop synthetic cannabinoid treatments commanding billion-dollar valuations, plant-touching cannabis companies trading on major exchanges face systematic exclusion from sector-specific funds. This creates an arbitrage opportunity as medical cannabis operators like Curaleaf Holdings and Green Thumb Industries report gross margins exceeding 50% on medical sales.
Medical cannabis patient registrations grew 23% year-over-year in 2024, reaching 6.2 million active patients nationwide. States like Florida and Pennsylvania each surpassed $1 billion in annual medical sales, demonstrating market maturity that rivals traditional pharmaceutical categories. Yet healthcare ETF managers cite federal scheduling conflicts and compliance concerns as barriers to cannabis inclusion.
The exclusion becomes more pronounced as cannabis companies expand into pharmaceutical-grade manufacturing and clinical research partnerships. Several multi-state operators now operate under Good Manufacturing Practice standards, matching quality protocols required for traditional drug manufacturing. This operational evolution positions cannabis companies as legitimate healthcare players despite continued ETF exclusion.
Investor appetite for healthcare cannabis exposure grows as medical programs demonstrate consistent revenue growth independent of adult-use market volatility. The sector's defensive characteristics during economic uncertainty mirror traditional healthcare investments, yet remain accessible only through direct stock purchases or cannabis-specific ETFs trading at significant volume discounts to healthcare sector funds.